In Vitro Insider
#InVitroInsider (Vol 1)
Welcome to In Vitro Insider, your source for the latest developments, trends, and insights in the world of in vitro diagnostics (IVD). As the IVD industry continues to grow and evolve, it is more important than ever to stay informed about the latest technologies, regulations, and market trends.
Whether you're an IVD professional, a researcher, or just have a passion for all things biotech, In Vitro Insider is here to provide you with the knowledge and expertise you need to stay ahead of the curve. In each issue, we'll bring you the latest news from the world of IVD. So, join us as we explore the latest cutting-edge diagnostic technology and discover the latest breakthroughs in the field.
If you're interested in contributing to an upcoming edition or collaborating on a future project, please don't hesitate to reach out. I'd love to hear from you!
Company Spotlight:
This week's company spotlight goes to Droplet Biosciences, Inc as they come out of stealth securing $8 million in Seed funding to advance its sensitive cancer diagnostics. The funding round was led by The Engine . The company, which was founded in 2021 by Theresa Tribble and Stan Lapidus , alongside scientific co-founders Jose P. Zevallos MD MPH and Aadel Chaudhuri, MD PhD Droplet uses lymphatic fluid to provide earlier and more sensitive cancer diagnostics.
Their groundbreaking non-invasive process collects surgical drain fluid after tumor removal, which is rich in T-cells, proteins, and other biomarkers that can offer insights into the body's immune response to cancer with greater sensitivity than blood.
The company's initial application is detecting residual disease in head and neck cancer patients immediately after surgery. The newly acquired funds will be used to accelerate the company's development efforts.
Collaboration of the week:
Exai Bio announced a collaboration agreement with Quantum Leap Healthcare Collaborative (QLHC) to broaden the use of its RNA-based liquid biopsy platform in the I-SPY 2 TRIAL.
The aim is to monitor patients' treatment response and disease burden in the trial, which studies multiple novel treatment arms for women with newly diagnosed, locally advanced breast cancer. The collaboration follows positive initial data from the trial, which demonstrated that orphan non-coding RNAs (lncRNA), a novel class of small RNA biomarkers, were a significant predictor of patient outcomes.
The expanded agreement is expected to increase the evidence for oncRNAs as a predictor of clinical outcomes and measurement of treatment response in a larger cohort of patients and across more therapies within I-SPY 2.
“We are delighted to extend our participation in such a groundbreaking trial, and to continue to demonstrate that our RNA-based approach can more effectively inform care decisions in a larger cohort of patients and across multiple therapies" said Pat Arensdorf Chief Executive Officer at Exai.
Recommended by LinkedIn
The Latest in IVD:
🩸 Mercy BioAnalytics, Inc. has secured a $41 million Series A financing round led by Novalis LifeSciences, which the company plans to use to further develop its Mercy Halo test.
🩸 OraSure Technologies and nRichDX Collaborate on Urine Collection Device for Cell-Free DNA
🩸 Genialis has raised $13 million in a series A. The company intends to use the funds to expand its store of clinically validated biomarker models, which are used for personalized cancer diagnosis.
🩸 T2 Biosystems shares have failed to meet a minimum $1 per share closing price for 30 consecutive days, which may result in the delisting of the firm's shares.
🩸 Sysmex America, Inc. & Cerca Biotech sign a distribution agreement on breast cancer assay
🩸 Theralink Technologies, Inc. . acquires immunotherapy biomarker patent from the Vanderbilt University
🩸 Oncocyte Corporation Prices $13.9M Stock Offering, Reports 69 Percent Drop in Preliminary Q4
Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag #InVitroInsider, and follow my page to participate in biweekly polls to share your insight!
If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me!
Thank you for featuring our work!